Ruxolitinib for Myelofibrosis – An Update of Its Clinical Effects
Ruxolitinib, a JAK1/JAK2 inhibitor, significantly improves splenomegaly and symptoms in intermediate-2 or high-risk myelofibrosis patients, as shown in COMFORT-I and COMFORT-II trials. Despite dose-dependent anemia and thrombocytopenia, adverse effects were manageable. Long-term data confirm durable benefits across patient subgroups, with potential survival improvement.
Reference News
Ruxolitinib for Myelofibrosis – An Update of Its Clinical Effects
Ruxolitinib, a JAK1/JAK2 inhibitor, significantly improves splenomegaly and symptoms in intermediate-2 or high-risk myelofibrosis patients, as shown in COMFORT-I and COMFORT-II trials. Despite dose-dependent anemia and thrombocytopenia, adverse effects were manageable. Long-term data confirm durable benefits across patient subgroups, with potential survival improvement.